Evidence map›Paper›PMID 33748824›Full record

ArticleImmunotherapy advances2021

Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells.

Gessa Sugiyarto, David Prossor, Osman Dadas, E David Arcia-Anaya, Tim Elliott, Edward James

Open access · bronzeAbstract read
In one paragraph

Article in Immunotherapy advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Reactivation of low avidity tumor-specific CD8Journal for immunotherapy of cancer · 2023
    Article
  9. IntroducingImmunotherapy advances · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Gessa SugiyartoCentre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.
David ProssorCentre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.
Osman DadasCentre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.
E David Arcia-AnayaCentre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.
Tim ElliottCentre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.
Edward JamesCentre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.ORCID 0000-0001-8638-7928
University Hospital Southampton NHS Foundation Trust · GB

Funding

Cancer Research UK A16997
6 · The paper itself

Abstract

objectivesRegulatory T cells (Treg) play a major role in the suppression of protective anti-tumour T cell responses. In the CT26 BALB/c murine model of colorectal carcinoma, Tregs differentially suppress responses to two characterised CD8+ T epitopes, AH1 and GSW11, which results in an absence of detectable IFN-γ-producing GSW11-specific T cells in the spleen and lymph nodes of tumour challenged mice. Activation of GSW11-specific T cells correlates with protection against tumour progression. We wanted to examine the presence of non-functional GSW11-specific T cells in Treg replete and depleted mice, assess their phenotype and their affinity compared to AH1-specific T cells.

methodsWe used peptide-specific tetramers to identify tumour-specific CD8+ T cells and assessed the cell surface expression of markers associated with exhaustion (PD-1, Tim3 and Lag-3) and their function by IFN-g production using flow cytometry. We also assessed the T cell receptor (TcR) clonality of tumour-specific T cells. Tetramer competition assays were performed to determine the relative affinity of identified TcR.

resultsHere, we show that GSW11-specific T cells are in fact induced in Treg-replete, CT26-bearing mice, where they make up the majority of tumour-infiltrating CD8+ lymphocytes, but exhibit an 'exhausted' phenotype. This dysfunctional phenotype is induced early in the anti-tumour response in tumours. Depletion of Tregs prior to tumour challenge correlates with an altered T cell receptor (TcR) repertoire. Moreover, the avidity of GSW11-specific TcRs that expanded in the absence of Tregs was significantly lower compared with TcRs of CD8+populations that were diminished in protective anti-tumour responses.

conclusionOur results indicate that Tregs suppress the induction of protective anti-tumour T cell responses and may signify that low-avidity T cells play an important role in this protection.

Indexed as

antigen presentationimmunotherapyregulatory T celltumour immunity

Identifiers

PMID33748824
PMCPMC7958313
OpenAlexW3109198953

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.